Davanat
As of the edition of 20 October 2026, Davanat is a drug: stopped in 2009; acts on LGALS1 and LGALS3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2009
- Kind
- Unknown
- Registered trials
- 4, 3 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Skin and connective tissue; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Davanat.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 0 | 0 | 3 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Galectin Therapeutics | Lead sponsor of trials | 2003 to now |